Health Condition 1: L438- Other lichen planus
Conditions
Interventions
Intervention1: Tofacitinib: Patients in this arm with oral lichen planus will receive oral tablet tofacitinib 5 mg twice daily for a period of 6 months.
Control Intervention1: topical triamcinolone ac
Sponsors
ostgraduate Institute of Medical Education and Research Chandigarh
Eligibility
Inclusion criteria
Inclusion criteria: 1. Clinician-confirmed diagnosis of symptomatic oral lichen planus having exclusive oral involvement or predominant oral involvement with few cutaneous lesions 2. Patients aged between 18-60 years of age 3. Patients providing informed consent and are willing to follow up monthly for at least 6 months
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating women 2. Women with childbearing potential who are unwilling to follow reliable methods of contraception
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Proportion of patients achieving 75% reduction in Oral Disease Severity Score (ODSS) proposed by Escudier et al at the end of 6 months of therapy 2. Proportion of patients achieving a Thongprasom et al score of 1/2 at the end of 6 months of therapy Timepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change in pain score based on Visual analogue scale (VAS) 2. Change in oral health-related quality of life based on oral health impact profile 14 score (OHIP-14) 3. Percentage change in the clinical scoring system at the end of 6 months of therapy Timepoint: 6 months | — |
Countries
India
Contacts
Public ContactDr Dipankar De
Postgraduate Institute of Medical Education and Research, Chandigarh
Outcome results
None listed